Edgewise Therapeutics, Inc.EWTXNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 88% recommend buying.

Consensus Rating

Buy

8 analysts·Limited coverage

88%

Rating Distribution

Strong Buy

00%

Buy

788%

Hold

00%

Sell

113%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Current price is 30% above analyst consensus — significant downside expected.

Bear Case

$20.00

-30%

Consensus

$20.00

-30%

Bull Case

$20.00

+-30%

Price Range8 analysts

Low

Consensus

High

$20.00

Current Target

Current Price

$28.69

Above Target

$8.69

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-1.94(9 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+1192.49%

EPS—

FY2028

Rev+469.06%

EPS—

FY2029

Rev+176.74%

EPS—

Earnings Surprises

Beat rate:75%(9/12 quarters)

Avg surprise:+5.5%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Sep 24, 2025Goldman Sachs

Goldman Sachs assigns Neutral rating to Edgewise Therapeutics

Target:$20.00

+20.6%from $16.59

Mar 7, 2025Scotiabank

Edgewise Therapeutics initiated with an Outperform at Scotiabank

Target:$50.00

+78.5%from $28.01

Dec 5, 2024Truist Financial

Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX), 'have reasons to believe that EWTX's study is not the study in question'

Target:$50.00

+58.4%from $31.57

Oct 11, 2024Piper Sandler

Piper Sandler Reiterates Overweight Rating on Edgewise Therapeutics (EWTX)

Target:$51.00

+67.5%from $30.45

Sep 20, 2024RBC Capital

Edgewise Therapeutics (EWTX) PT Raised to $42 at RBC Capital

Target:$42.00

+42.4%from $29.50

Sep 19, 2024Leerink Partners

Edgewise Therapeutics (EWTX) PT Raised to $42 at Leerink Partners

Target:$42.00

+42.4%from $29.50

Jul 1, 2024Piper Sandler

Piper Sandler Reiterates Overweight Rating on Edgewise Therapeutics (EWTX)

Target:$48.00

+166.5%from $18.01

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance